Tests ADX-038 injections against placebo for geographic atrophy in older adults
Tests ADX-038 injections against placebo in adults with geographic atrophy from macular degeneration.
Plain-language title generated from the registry record
Registry title: Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
Key facts
- Where
- Austin, Bakersfield, Bellaire, Beverly Hills, Dallas, Erie, Gilbert, Hagerstown, Huntington Beach, McAllen, Orlando, Phoenix, Poway, Reno, Riverside, Round Rock, San Antonio, St. George, The Woodlands, Walnut Creek, and Wildwood, United StatesSee the 21 sites
- Phase
- Phase 2
Where in United States
- AustinAustin, United StatesTaking people
- BakersfieldBakersfield, United StatesTaking people
- BellaireBellaire, United StatesTaking people
- Beverly HillsBeverly Hills, United StatesTaking people
- DallasDallas, United StatesTaking people
- ErieErie, United StatesNo longer taking part
- GilbertGilbert, United StatesTaking people
- HagerstownHagerstown, United StatesTaking people
- Huntington BeachHuntington Beach, United StatesTaking people
- McAllenMcAllen, United StatesTaking people
- OrlandoOrlando, United StatesTaking people
- PhoenixPhoenix, United StatesTaking people
- PowayPoway, United StatesTaking people
- RenoReno, United StatesTaking people
- RiversideRiverside, United StatesNot yet recruiting
- Round RockRound Rock, United StatesTaking people
- San AntonioSan Antonio, United StatesTaking people
- St. GeorgeSt. George, United StatesTaking people
- The WoodlandsThe Woodlands, United StatesTaking people
- Walnut CreekWalnut Creek, United StatesTaking people
- WildwoodWildwood, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- ADARx Pharmaceuticals, Inc.
- Trial code
- NCT06990269EU 2025-521779-30-00
- Record updated
- 3 September 2026
- Original description
Phase 2 study is designed to assess the efficacy of ADX-038 compared with placebo in participants with GA secondary to AMD. Safety, pharmacokinetics (PK), and pharmacodynamics (PD) will also be assessed.Read full original descriptionShow less
A Phase 2, Randomized, Masked, Placebo-Controlled Study of Subcutaneously Administered ADX-038 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
Phase 2 study is designed to assess the efficacy of ADX-038 compared with placebo in participants with GA secondary to AMD. Safety, pharmacokinetics (PK), and pharmacodynamics (PD) will also be assessed.
Inclusion: Clinical diagnosis of GA of the macula secondary to AMD; GA lesions between 2.5 and 12.5 mm2 at screening; Sufficiently clear ocular media, adequate pupillary dilation and fixation to permit quality fundus imaging in the study eye as described in the protocol; Willing and able to comply with clinic visits and study-related procedures, including completion of the full series of meningococcal vaccinations and pneumococcal vaccination required per protocol.
Exclusion: Use of intravitreal complement inhibitors in study eye; Has active ocular disease that compromises or confounds visual function; History of surgery for retinal detachment; Has ocular condition other than GA secondary to AMD; Active viral, bacterial or fungal infection; History of choroidal neovascularization in the study eye; Has GA secondary to causes other than AMD; Hereditary or acquired complement deficiency; Liver injury as evidenced by abnormal liver function tests; Donating blood.